Guardant Health Shares Climb to Five-Year High on UnitedHealth Coverage Consideration
UNH•Shares of Guardant Health hit five-year highs after UnitedHealth indicated it may cover its Shield blood test for early cancer detection. BTIG called the move a “huge” derisking event and Citi projects insurer backing could drive significant revenue growth for Guardant’s screening business.
1. UnitedHealth Signals Potential Coverage
UnitedHealth has indicated it may include Guardant Health’s Shield blood test in its benefits network, offering non-invasive early cancer detection for its insured members. This would mark the first broad coverage of a liquid biopsy by the insurer and could set a precedent for payer adoption.
2. Analyst Responses
BTIG described the insurer’s consideration as a “huge” derisking event for Guardant’s screening segment, which propelled shares to their highest level in over five years. Citi noted that UnitedHealth backing could validate clinical utility and substantially reduce reimbursement risk.
3. Financial Impact for Guardant Health
Insurer adoption could unlock significant new revenue streams for Guardant’s testing business, potentially boosting annual screening revenues once coverage begins. The partnership may also attract interest from other payers, further supporting Guardant’s growth trajectory.
